Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 23Kidney Neoplasms 10Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Carcinoma 6Melanoma 4Lung Neoplasms 4Colorectal Neoplasms 4Neoplasm Metastasis 3Carcinoma, Hepatocellular 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Kidney Diseases 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Adenoid Cystic 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1

Interventions

3-Iodobenzylguanidine 3cabozantinib 2pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1Sunitinib 1Radiosurgery 1Phenoxybenzamine 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Iodine-131 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Axitinib 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Paraganglioma × Axitinib × Clear all
NCT01967576 2021-01-06

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
14 enrolled 12 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡